|
Globally compliant, innovation-driven supplier and mfr of high-quality APIs
|
|
December 06 , 2025
|
|
|
Zhejiang ChengYi Pharmaceutical Co. Ltd is a rapidly emerging, innovation-driven company specialising in the manufacture and supply of high-quality Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. Built on a foundation of reliability, scientific excellence, and adherence to global standards, the company has transitioned from a raw material supplier to a full-scale producer of its own proprietary products, serving as a trusted partner to the global pharmaceutical industry.
Core Capabilities & Manufacturing
The company operates advanced manufacturing facilities that integrate precision technology, stringent quality-driven processes, and a highly skilled workforce. This infrastructure supports the company's recent milestone: the full-scale production of its own API and intermediate product pipeline.
• Strategic Sourcing Model: Zhejiang employs a unique hybrid raw-material sourcing model. This dual strategy—manufacturing key raw materials in-house while procuring specialised inputs from reliable external partners ensures supply security, cost efficiency, and enhanced traceability for consistent product quality.
Regulatory Compliance & Quality
Zhejiang prioritises a structured and rigorous approach to regulatory compliance, adhering to specific quality requirements for each product. This commitment is evidenced by:
• Successful clearance of FDA audits.
• Adherence to CMT specifications.
• A robust internal Quality Management System.
This strong compliance record is a key strength, opening pathways to high-regulation markets and solidifying global customer confidence.
Global Reach & Market Focus
The company is a globally connected enterprise with a significant international footprint:
• Current Export Markets: New Zealand, South Africa, Europe, and India.
• Indian Market Strategy: Zhejiang is actively expanding its presence in India, where it currently serves two key customers. The strategy for growth involves enhancing its product portfolio and distribution capabilities within the region.
Research & Development (R&D)
R&D is a major engine for the company's growth, supported by modern analytical and testing laboratories. The dedicated team focuses on:
• Developing new molecules.
• Optimising processes for efficiency.
• Improving product purity and yield.
These continuous innovations ensure Zhejiang remains ahead of evolving industry demands and regulatory landscapes.
Future Outlook
With robust international partnerships, continuous investment in technology and quality, and a strong product pipeline, Zhejiang is poised for significant global growth, committed to delivering reliable quality and contributing to a healthier world through advanced pharmaceutical solutions.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|